Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic pancreatic cancer with metastases amenable to biopsy~* Willingness to provide tissue and blood samples for research purposes~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1~Exclusion Criteria:~* History of islet cell, acinar cell, or cystadenocarcinomas~* Prior cytotoxic chemotherapy for metastatic disease, except prior gemcitabine or FOLFIRINOX (5FU + leucovorin + irinotecan + oxaliplatin)~* Radiation therapy, immunotherapy or biologic therapy \<28 days prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY2090314 + Gemcitabine (Type: EXPERIMENTAL): LY2090314 given intravenously (IV) on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 milligram/square meter (mg/m\^2) gemcitabine given IV on days 1, 8 and 15. Cohort closed to new enrollment per protocol addendum.
- LY2090314 + FOLFOX (Type: EXPERIMENTAL): LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), and 15 in 28 day cycle in combination with FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin) given IV, on days 1 and 15 in 28 day cycle.
- LY2090314 + Gemcitabine + Nab-paclitaxel (Type: EXPERIMENTAL): LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 mg/m\^2 gemcitabine + 125 mg/m\^2 nab-paclitaxel given IV on days 1, 8 and 15 in 28-day cycle. New cohort opened per protocol amendment.

Based on this trial design, predict the completion outcome and termination type (if applicable).